Tear antibodies to SARS‐CoV‐2: implications for transmission. Issue 11 (1st November 2021)
- Record Type:
- Journal Article
- Title:
- Tear antibodies to SARS‐CoV‐2: implications for transmission. Issue 11 (1st November 2021)
- Main Title:
- Tear antibodies to SARS‐CoV‐2: implications for transmission
- Authors:
- Selva, Kevin J
Davis, Samantha K
Haycroft, Ebene R
Lee, Wen Shi
Lopez, Ester
Reynaldi, Arnold
Davenport, Miles P
Kent, Helen E
Juno, Jennifer A
Chung, Amy W
Kent, Stephen J - Abstract:
- Abstract: Objectives: SARS‐CoV‐2 can be transmitted by aerosols, and the ocular surface may be an important route of transmission. Little is known about protective antibody responses to SARS‐CoV‐2 in tears after infection or vaccination. We analysed the SARS‐CoV‐2‐specific IgG and IgA responses in human tears after either COVID‐19 infection or vaccination. Methods: We measured the antibody responses in 16 subjects with COVID‐19 infection for an average of 7 months before, and 15 subjects before and 2 weeks post‐Comirnaty (Pfizer‐BioNtech) vaccination. Plasma, saliva and basal tears were collected. Eleven pre‐pandemic individuals were included as healthy controls. Results: IgG antibodies to spike and nucleoprotein were detected in tears, saliva and plasma from subjects with prior SARS‐CoV‐2 infection in comparison with uninfected controls. While receptor‐binding domain (RBD)‐specific antibodies were detected in plasma, minimal RBD‐specific antibodies were detected in tears and saliva. By contrast, high levels of IgG antibodies to spike and RBD, but not nucleoprotein, were induced in tears, saliva and plasma of subjects receiving 2 doses of the Comirnaty vaccine. Increased levels of IgA1 and IgA2 antibodies to SARS‐CoV‐2 antigens were detected in plasma following infection or vaccination but were unchanged in tears and saliva. Comirnaty vaccination induced high neutralising Abs in the plasma, but limited neutralising antibodies were detected in saliva or tears. Conclusion:Abstract: Objectives: SARS‐CoV‐2 can be transmitted by aerosols, and the ocular surface may be an important route of transmission. Little is known about protective antibody responses to SARS‐CoV‐2 in tears after infection or vaccination. We analysed the SARS‐CoV‐2‐specific IgG and IgA responses in human tears after either COVID‐19 infection or vaccination. Methods: We measured the antibody responses in 16 subjects with COVID‐19 infection for an average of 7 months before, and 15 subjects before and 2 weeks post‐Comirnaty (Pfizer‐BioNtech) vaccination. Plasma, saliva and basal tears were collected. Eleven pre‐pandemic individuals were included as healthy controls. Results: IgG antibodies to spike and nucleoprotein were detected in tears, saliva and plasma from subjects with prior SARS‐CoV‐2 infection in comparison with uninfected controls. While receptor‐binding domain (RBD)‐specific antibodies were detected in plasma, minimal RBD‐specific antibodies were detected in tears and saliva. By contrast, high levels of IgG antibodies to spike and RBD, but not nucleoprotein, were induced in tears, saliva and plasma of subjects receiving 2 doses of the Comirnaty vaccine. Increased levels of IgA1 and IgA2 antibodies to SARS‐CoV‐2 antigens were detected in plasma following infection or vaccination but were unchanged in tears and saliva. Comirnaty vaccination induced high neutralising Abs in the plasma, but limited neutralising antibodies were detected in saliva or tears. Conclusion: Both infection and vaccination induce SARS‐CoV‐2‐specific IgG antibodies in tears. RBD‐specific IgG antibodies in tears were induced by vaccination but were not present 7 months post‐infection. This suggests the neutralising antibodies may be low in the tears late following infection. Abstract : The ocular surface may be an important route of SARS‐CoV‐2 transmission. We found SARS‐CoV‐2‐specific antibodies in tears, saliva and plasma from participants either convalescent from COVID‐19 or receiving the Pfizer Comirnaty vaccine. … (more)
- Is Part Of:
- Clinical & translational immunology. Volume 10:Issue 11(2021)
- Journal:
- Clinical & translational immunology
- Issue:
- Volume 10:Issue 11(2021)
- Issue Display:
- Volume 10, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 10
- Issue:
- 11
- Issue Sort Value:
- 2021-0010-0011-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-11-01
- Subjects:
- antibodies -- COVID‐19 -- neutralisation -- saliva -- SARS‐CoV‐2 -- tears
Immunologic diseases -- Periodicals
Immunology -- Periodicals
Clinical medicine -- Periodicals
Immune System Diseases -- therapy
Immunotherapy
Immunologic Factors -- therapeutic use
Translational Medical Research
Molecular Targeted Therapy
Clinical medicine
Immunologic diseases
Immunology
Periodicals
Periodicals
Fulltext
Internet Resources
Periodicals
616.079 - Journal URLs:
- http://www.nature.com/cti/index.html ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/2610/ ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0068 ↗
http://www.nature.com/ ↗
http://www.nature.com/cti/index.html ↗ - DOI:
- 10.1002/cti2.1354 ↗
- Languages:
- English
- ISSNs:
- 2050-0068
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20034.xml